Clinical trials: Overweight, Obesity
COPD (Chronic Obstructive Pulmonary Disease), Obesity Hypoventilation Syndrome (OHS)
Assessment of Breathing Pattern During NIV
COPD and OHS are respiratory conditions that disrupt normal breathing. Positive airway pressure, specifically Non-Invasive Ventilation (NIV), has been shown to improve breathing and reduce symptoms in patients with these…
- Trial name
- NCT06682286
- Testing
- NIV mask A, NIV mask B
- Where
- New Zealand
- Volunteers
- 40 people
- Sponsor
- Fisher and Paykel Healthcare
Obesity, Morbid
Early Feasibility Study: Assessment of Self-Forming Magnetic Anastomosis Device and Delivery System (SFM) in Obese Patients, When Used to Create a Duodenal-Ileal Anastomosis Post SG (SNAP-PS), or Used to Create a Jejuno-Jejunal (J-J) Anastomosis
The objectives of this study are to assess the initial safety and device functionality of the SFM Anastomosis System including delivery systems when used to create a duodenal-ileal (D-I) anastomosis with patients with prior…
- Trial name
- GIW-J-J (NCT06200896)
- Testing
- Self Forming Magnets used to Create A Compression Anastomosis
- Where
- Chile
- Volunteers
- 28 people
- Sponsor
- GI Windows, Inc.
Obesity
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
The study tests if treatment with cagrilintide delays the transmission of electrical signals in the heart compared to treatment with placebo.
- Trial name
- NCT05804162
- Testing
- Cagrilintide, Moxifloxacin
- Where
- Germany
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity, Weight Loss
BEFORE Study, Efficacy of Refigura
The BEFORE study ((B) EFficacy Of REfigura) is designed to demonstrate the efficacy of REFIGURA®. It is a double-blind, randomized, monocentric study.
- Conditions
- Overweight and Obesity, Weight Loss, Efficacy, Self
- Trial name
- NCT03557424
- Testing
- Polyglucosamine Glucomannan normal dose (Verum), Polyglucosamine Glucomannan high dose (Verum)
- Where
- Germany
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Heilpflanzenwohl AG
Overweight and/or Obesity
STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY
The purpose of the study is to evaluate the effect of formulation on relative bioavailability of PF-06882961.
- Trial name
- NCT04616339
- Testing
- PF-06882961 100 mg
- Where
- Belgium
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Trial name
- NCT07458269
- Testing
- Ribupatide
- Where
- 35 sites in United States
- Volunteers
- 264 people
- Sponsor
- Kailera
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes, Obesity
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of…
- Conditions
- Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
- Trial name
- TRIUMPH-2 (NCT05929079)
- Testing
- Retatrutide
- Where
- 98 sites in United States, Argentina and 6 more
- Volunteers
- 1,152 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.
- Trial name
- NCT03479762
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 105 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program
The purpose of this study is to compare the efficacy and safety of topiramate 96mg and 192mg daily) with placebo in the treatment of obesity following an intensive non-pharmacologic weight loss program.
- Trial name
- NCT00236600
- Testing
- topiramate
- Volunteers
- 561 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity, Over-weight
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.
- Conditions
- Obesity, Over-weight, Prader-Willi Syndrome
- Trial name
- NCT01818921
- Testing
- ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Zafgen, Inc.
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet
The purpose of this study is to determine the efficacy and safety of topiramate compared with placebo in obese, Type 2 diabetic patients on a controlled diet.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231530
- Testing
- topiramate
- Volunteers
- 541 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypertension
International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan
The purpose of this study is to estimate antihypertensive effect of azilsartan medoxomil (Edarbi®) therapy on blood pressure in participants with overweight or obesity in routine clinical practice of hypertension (HTN) treatment…
- Trial name
- NCT02756819
- Testing
- Azilsartan Medoxomil
- Where
- 66 sites in Kazakhstan, Russia
- Volunteers
- 1,945 people
- Sponsor
- Takeda
Overweight, Obesity
Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients
This is a randomized, double-blind, placebo-controlled, dose-finding, Phase 2a study designed to evaluate the safety and efficacy of KDS2010 in overweight or obese patients.
- Conditions
- Overweight, Obesity, Obese Patients
- Trial name
- NCT07009171
- Testing
- KDS2010
- Where
- 3 sites in South Korea
- Volunteers
- 75 people
- Sponsor
- NeuroBiogen Co., Ltd
Type 2 Diabetes, Obese
The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes
The objective of this study is to investigate the efficacy and safety of the GOLO for Life® Plan (G4LP) and Release supplementation on glycemic control and weight in overweight and obese adults with Prediabetes or Type 2…
- Conditions
- Type 2 Diabetes, Obese, Overweight, Prediabetes
- Trial name
- NCT05844644
- Testing
- Release
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Golo
Type 2 Diabetes Mellitus
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period
Primary Objectives: Main study: To assess in overweight to obese subjects and type 2 diabetes mellitus (T2DM) patients not requiring anti-diabetic pharmacotherapy the safety and tolerability of 3 different dose escalation…
- Trial name
- NCT03414736
- Testing
- SAR425899
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sanofi
Overweight, Obesity
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
- Trial name
- NCT07523711
- Testing
- COC, Maridebart Cafraglutide
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Amgen
Overweight, Obesity
Individual Factors Related to Chronic Low-grade Inflammation and Cardiometabolic Disease Risk
The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity.
- Conditions
- Overweight, Obesity, Metabolic Syndrome, Healthy
- Trial name
- PINEAPPL (NCT06355544)
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Integrative Phenomics
Obesity
A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant
This study medicine NNC0487-0111 to improve the treatment options for people living with overweight and obesity or with type 2 diabetes.
- Trial name
- NCT06461039
- Testing
- NNC0487-0111 A, NNC0487-0111 C, Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obesity, Type2 Diabetes Mellitus
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study…
- Trial name
- NCT05762471
- Testing
- GSBR-1290
- Where
- 4 sites in United States
- Volunteers
- 142 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.